NasdaqGS:INDVPharmaceuticals
Indivior Pharmaceuticals (INDV) Q4 Net Margin Jump To 16.9% Tests Bullish Narratives
Indivior Pharmaceuticals (INDV) has come off a strong finish to 2025, with Q4 total revenue of US$358 million, basic EPS of US$0.82, and trailing twelve month figures showing total revenue of US$1.2 billion and basic EPS of US$1.68. Over recent quarters the company has seen revenue move from US$299 million in Q4 2024 to US$358 million in Q4 2025, while quarterly basic EPS shifted from US$0.17 in Q4 2024 to US$0.82 in Q4 2025. This sets up the latest results release as a key check on how...